Journals / Turkish Journal of Biology / 2014 / Cilt: 38 - Sayı: 6

Triumph or tragedy: progress in cancer

Pages
701–707
Publication Date
2014-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, we discuss some future perspectives to give some insight into cancer research and debunk the old view that pouring money into cancer research is the only way to overcome this dreadful disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer is probably the number one research area among all human endeavors, receiving the largest portion of science funding in most countries.
📊
Key Findings & Data:In this review, our aim is not to establish a comprehensive understanding of cancer, which is essentially impossible, but to outline, in a more provocative way, why cancer research in the pursuit of a cure did not live up to its promise, as the death rate from cancer has not changed much after almost half a century.
💡
Conclusion & Impact:In addition, we discuss some future perspectives to give some insight into cancer research and debunk the old view that pouring money into cancer research is the only way to overcome this dreadful disease.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Cancer · cancer research · cancer statistics

Abstract

Cancer is probably the number one research area among all human endeavors, receiving the largest portion of science funding in most countries. This is because cancer remains one of the oldest conundrums among all human maladies. Although we now have a greater understanding of the biological and molecular basis of cancer, its diagnosis and therapy still pose great challenges. In this review, our aim is not to establish a comprehensive understanding of cancer, which is essentially impossible, but to outline, in a more provocative way, why cancer research in the pursuit of a cure did not live up to its promise, as the death rate from cancer has not changed much after almost half a century. In addition, we discuss some future perspectives to give some insight into cancer research and debunk the old view that pouring money into cancer research is the only way to overcome this dreadful disease.

Özet

Cancer is probably the number one research area among all human endeavors, receiving the largest portion of science funding in most countries. This is because cancer remains one of the oldest conundrums among all human maladies. Although we now have a greater understanding of the biological and molecular basis of cancer, its diagnosis and therapy still pose great challenges. In this review, our aim is not to establish a comprehensive understanding of cancer, which is essentially impossible, but to outline, in a more provocative way, why cancer research in the pursuit of a cure did not live up to its promise, as the death rate from cancer has not changed much after almost half a century. In addition, we discuss some future perspectives to give some insight into cancer research and debunk the old view that pouring money into cancer research is the only way to overcome this dreadful disease.

🔖

Cite This Article

ERENLER, A. Ş., GEÇKİL, H. (2014). Triumph or tragedy: progress in cancer. Turkish Journal of Biology, Cilt: 38 - Sayı: 6, 701–707. https://ajindex.com/articles/181589

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Agrawal V, Alpini SEJ, Stone EM, Frenkel EP, Frankel AE (2012). Targeting methionine auxotrophy in cancer: discovery & exploration. Expert Opin Biol Th 12: 53–61.
  2. Axelrod R, Axelrod DE, Pienta KJ (2006). Evolution of cooperation among tumor cells. P Natl Acad Sci USA 103: 13474–13479.
  3. Baker NM, Der CJ (2013). Cancer: Drug for an ‘undruggable’ protein. Nature 497: 577–578.
  4. Carlos RC, Dempsey AF, Patel DA, Dalton VK (2010). Cervical cancer prevention through human papillomavirus vaccination using the “teachable moment” for educational interventions. Obstet Gynecol 115: 834–838.
  5. DeBerardinis RJ, Thompson CB (2012). Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148: 1132– 1144. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW (2010). Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126: 2762–2772.
  6. Der CJ, Krontiris TG, Cooper GM (1982). Transforming genes of human bladder and lung-carcinoma cell-lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. P Natl Acad Sci 79: 3637–3640.
  7. Eckhouse S, Lewison G, Sullivan R (2008). Trends in the global funding and activity of cancer research. Mol Oncol 2: 20–32.
  8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–2917.
  9. Ferrari M (2013). Slipping past cancer’s barriers. Am Sci 101: 430–433.
  10. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR (2004). A census of human cancer genes. Nat Rev Cancer 4: 177–183.
  11. Geckil H, Gencer S, Uckun M (2004). Vitreoscilla hemoglobin expressing Enterobacter aerogenes and Pseudomonas aeruginosa respond differently to carbon catabolite and oxygen repression for production of L-asparaginase, an enzyme used in cancer therapy. Enzyme Microb Tech 35: 182–189.
  12. Gerlinger M (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 367: 976– 976. Greaves M, Maley CC (2012). Clonal evolution in cancer. Nature 481: 306–313.
  13. Harvey JJ (1964). An unidentified virus which causes the rapid production of tumours in mice. Nature 204: 1104–1105.
  14. Huang S (2013). Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells. Cancer Metast Rev 32: 423–448. International Cancer Genome Consortium, Hudson TJ, Anderson W, Art